Real-world outcomes among people receiving bictegravir/emtricitabine/tenofovir alafenamide: A comparison between those with and without advanced HIV-1 disease
Real-world outcomes among people receiving bictegravir/emtricitabine/tenofovir alafenamide: A comparison between those with and without advanced HIV-1 disease. // Journal of Infection and Public Health. – URL: https://www.sciencedirect.com/science/article/pii/S1876034126002856?dgcid=rss_sd_all
Real-world outcomes among people receiving bictegravir/emtricitabine/tenofovir alafenamide: A comparison between those with and without advanced HIV-1 disease. Journal of Infection and Public Health. https://www.sciencedirect.com/science/article/pii/S1876034126002856?dgcid=rss_sd_all
“Real-world outcomes among people receiving bictegravir/emtricitabine/tenofovir alafenamide: A comparison between those with and without advanced HIV-1 disease.” Journal of Infection and Public Health.
@article{article53829,
title = {Real-world outcomes among people receiving bictegravir/emtricitabine/tenofovir alafenamide: A comparison between those with and without advanced HIV-1 disease},
journal = {Journal of Infection and Public Health},
url = {https://www.sciencedirect.com/science/article/pii/S1876034126002856?dgcid=rss_sd_all}
}
Abstract Aim Discretionary foods and beverages contribute to poor diet quality and chronic disease. In Australia, intake exceeds dietary guideline recommendations and is unlikely to improve without substantial intervention. We examined...
ABSTRACT Background Ultra‐processed foods (UPFs) are a leading contributor to diet‐related chronic disease and socio‐ecological harm. Despite increasing recognition of these impacts, regulatory responses remain fragmented, focused on...